A novel prognostic index in patients with hepatocellular cancer waiting for liver transplantation Time-Radiological-response-Alpha-fetoprotein-INflammation (TRAIN) score

Annals of Surgery

Volumn 264, Issue 5, 2016, Pages 787-796

  Lai, Quirino ^a,b   Nicolini, Daniele ^c   Inostroza, Milton ^a   Iesari, Samuele ^a,b,c   Goffette, Pierre ^a   Agostini, Andrea ^c   Giovagnoni, Andrea ^c   Vivarelli, Marco ^c   Lerut, Jan ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c OSPEDALI RIUNITI   (Italy)

Author keywords

alpha fetoprotein slope; drop out; fast track approach; hepatocellular cancer; liver transplantation; mRECIST; neutrophil tolymphocyte ratio; recurrence; waiting time

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL PRACTICE; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; INTENTION TO TREAT ANALYSIS; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SURGICAL RISK; SURVIVAL RATE; TUMOR NECROSIS; TUMOR VOLUME; BLOOD; CARCINOMA, HEPATOCELLULAR; HOSPITAL ADMISSION; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PATIENT SELECTION; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SELECTION; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; WAITING LISTS;

EID: 84978646189     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001881     Document Type: Article

References (29)

1. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
2. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394-1403.
3. Mazzaferro V, Llovet JM, Miceli R, et al., Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis. Lancet Oncol. 2009;10:35-43.
4. Duvoux C, Roudot-Thoraval F, Decaens T, et al., Liver Transplantation French Study Group. Liver transplantation for hepatocellular carcinoma: A model including a-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986-994.
5. Vibert E, Azoulay D, Hoti E, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: A critical factor. Am J Transplant. 2010;10:129-137.
6. Lai Q, Avolio AW, Graziadei I, et al., European Hepatocellular Cancer Liver Transplant Study Group. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl. 2013;19:1108-1118.
7. Otto G, Schuchmann M, Hoppe-Lotichius M, et al. How to decide about liver transplantation in patients with hepatocellular carcinoma: Size and number of lesions or response to TACE?. J Hepatol. 2013;59:279-284.
8. Lai Q, Castro Santa E, Rico Juri JM, et al. Neutrophil and platelet-tolymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transpl Int. 2014;27:32-41.
9. Samoylova ML, Dodge JL, Yao FY, et al. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2014;20:937-944.
10. Halazun KJ, Patzer RE, Rana AA, et al. Standing the test of time: Outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology. 2014;60:1957-1962.
11. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: An update. Hepatology. 2011;53:1020-1022.
12. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943.
13. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-60.
14. Pinato DJ, Stebbing J, Ishizuka M, et al. A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI). J Hepatol. 2012;57:1013-1020.
15. Lai Q, Avolio AW, Lerut J, et al. Recurrence of hepatocellular cancer after liver transplantation: The role of primary resection and salvage transplantation in East and West. J Hepatol. 2012;57:974-979.
16. Harimoto N, Shirabe K, Nakagawara H, et al. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio. Transplantation. 2013;96:1008-1012.
17. Parisi I, Tsochatzis E, Wijewantha H, et al. Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within Milan criteria. Liver Transpl. 2014;20:1327-1335.
18. Lai Q, Lerut J. Inflammation-based scores and hepatocellular carcinoma: "Faithful friends are hard to find". Liver Transpl. 2014;20:1527-1528.
19. Lai Q, Avolio AW, Graziadei I, et al., European Hepatocellular Cancer Liver Transplant (EurHeCaLT) Study Group. Response to locoregional treatment and alpha-fetoprotein trend in liver transplant candidates for HCC: Dwarfs standing on the shoulders of giants. J Hepatol. 2014;60: 1331-1332.
20. Yao FY, Mehta N, Flemming J, et al. Downstaging of hepatocellular cancer before liver transplant: Long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61:1968-1977.
21. Mehta N, Dodge JL, Goel A, et al. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: Implications for the current organ allocation policy. Liver Transpl. 2013; 19:1343-1353.
22. Lai Q, Melandro F, Pinheiro RS, et al. Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: A brilliant star raises again. Int J Hepatol. 2012;2012:893103.
23. Hameed B, Mehta N, Sapisochin G, et al. Alpha-fetoprotein level>1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014;20:945-951.
24. Lai Q, Inostroza M, Rico Juri JM, et al. Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer. HPB (Oxford). 2015;17:1085-1095.
25. Toso C, Dupuis-Lozeron E, Majno P, et al. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list. Hepatology. 2012;56:149-156.
26. Vitale A, Volk ML, De Feo TM, et al., Liver Transplantation North Italy Transplant program (NITp) working group. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. J Hepatol. 2014;60:290-297.
27. Cucchetti A, Piscaglia F, Grigioni AD, et al. Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: A pilot study. J Hepatol. 2010;52:880-888.
28. CiccarelliO,Lai Q, GoffetteP, et al.Liver transplantation for hepatocellular cancer: UCL experience in 137 adult cirrhotic patients. Alpha-foetoprotein level and locoregional treatment as refined selection criteria. Transpl Int. 2012;25:867-875.
29. Terzi E, Ray Kim W, Sanchez W, et al. Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl. 2015;21:248-257.